Moderna’s long-term commercial thesis has always been bigger than COVID. If the mRNA platform can make better flu vaccines, respiratory combination shots, and pandemic-ready constructs, it becomes a perennial revenue generator rather than a product of a single crisis. FDA briefing documents released this week show regulators are increasingly open to approving Moderna’s experimental mRNA flu vaccine, indicating the shot met key study goals and may be effective in adults aged 65 and older—the population that accounts for the majority of flu-related hospitalizations and deaths. Endpoints News reported the FDA “provided tepid support” but “didn’t appear to raise any major concerns that could hinder its prospects.” If approved, this would be the first mRNA-based seasonal flu vaccine in the United States and would validate the mRNA platform beyond pandemic applications. It would also challenge the established flu vaccine market dominated by egg-based and cell-based products from Sanofi, Seqirus, and GSK. Separately, Daiichi Sankyo’s new R&D chief faces the challenge of “outrunning the very ADC gold rush the company helped ignite.” Curium won a patent fight with Novartis over Lu-177, strengthening its position ahead of the potential $7 billion Lantheus take-private. And four biotechs have raised at least $400 million in 2026 IPOs—the most in a single year since 2021.
Top Story: Moderna mRNA Flu Vaccine Gets Positive FDA Briefing Signal
What Happened: FDA briefing documents released ahead of an advisory committee meeting show that regulators are increasingly open to approving Moderna’s experimental mRNA flu vaccine. The documents indicate the shot met key study goals and may be effective in adults aged 65 and older.
Why mRNA Could Make a Better Flu Vaccine
The seasonal flu vaccine market has been built on technology that is decades old. The majority of flu vaccines are produced using fertilized chicken eggs—a manufacturing process that takes six or more months from strain selection to finished product. Cell-based and recombinant alternatives have improved the timeline and reduced some manufacturing limitations, but all current flu vaccines share a fundamental constraint: the long production cycle means the vaccine strain must be selected months before flu season begins. When the circulating strains drift from the vaccine strains during that lag period, the vaccine becomes less effective. This strain mismatch is one of the primary reasons flu vaccine effectiveness varies so widely from year to year.
mRNA changes the manufacturing timeline entirely. An mRNA flu vaccine can be designed and produced in weeks rather than months, allowing closer alignment between the vaccine strain and the strains actually circulating in the population. This speed advantage could meaningfully improve flu vaccine effectiveness in seasons where strains drift late, giving public health officials more time to make optimal strain selection decisions.
The efficacy signal in adults 65 and older is particularly important. This population accounts for the majority of flu-related deaths and hospitalizations. Existing vaccines for this age group include high-dose formulations (Sanofi’s Fluzone High-Dose) and adjuvanted vaccines (Seqirus’s Fluad) that are designed to overcome the weaker immune responses that occur with aging. An mRNA flu vaccine that demonstrates strong efficacy in this population would compete directly with these premium products and potentially capture significant market share.
Endpoints News reported the FDA “provided tepid support” but “didn’t appear to raise any major concerns that could hinder its prospects.” The characterization is important: “tepid support” is not enthusiastic endorsement, but the absence of major concerns suggests the regulatory path is navigable. An advisory committee meeting is the next step, and a positive recommendation there would be the final hurdle before potential approval.
What Approval Would Mean for Moderna
An approved mRNA flu vaccine would transform Moderna from a pandemic vaccine company into a platform vaccine company. The commercial implications extend beyond flu itself. If mRNA works for seasonal flu, the same manufacturing infrastructure can produce combination vaccines (flu plus COVID, flu plus RSV) that reduce the number of shots patients need each year. Moderna has been developing combination respiratory vaccines alongside its single-pathogen programs. An approved flu vaccine validates the platform for the combinations that follow.
The competitive impact on the existing flu vaccine market would be significant. Sanofi (Fluzone), Seqirus (Flucelvax, Fluad), and GSK (Fluarix) dominate the current market. An mRNA alternative that offers faster manufacturing, better strain matching, and strong efficacy in the 65-plus population would challenge every incumbent. The disruption would not be overnight—flu vaccine purchasing is contracted through healthcare systems and pharmacy chains with established supplier relationships—but the clinical and manufacturing advantages of mRNA create a compelling case for adoption over time.
Our Pro brief analyzes the mRNA flu vaccine’s commercial potential against the established market, models the manufacturing speed advantage and its impact on strain match effectiveness, and assesses what approval means for Moderna’s combination respiratory vaccine strategy. [Details below.]
Daiichi Sankyo’s New R&D Chief Must “Outrun the ADC Gold Rush”
What Happened: Fierce Biotech profiled Daiichi Sankyo’s new head of R&D on June 17, framing the challenge as “outrunning the very ADC gold rush the company helped ignite.”
The Innovator’s Dilemma in ADCs
Daiichi Sankyo co-developed Enhertu with AstraZeneca and created the template for the modern ADC wave. The company proved that ADCs could deliver transformative efficacy in solid tumors—not just as late-line salvage therapy but as practice-changing treatment across breast cancer, lung cancer, and gastric cancer. The success inspired an industry-wide rush into ADC development that has accelerated throughout 2026.
The competitive landscape Daiichi Sankyo now faces is dramatically different from the one it helped create. Gilead spent approximately $15 billion on ADC-related acquisitions. Merck’s sac-TMT partnership with Kelun-Biotech produced two Phase 3 wins (endometrial cancer plus the 65% PFS improvement over Keytruda in lung cancer). Lilly acquired CrossBridge for dual-payload ADC technology. Padcev plus Keytruda showed 55.8% pathologic complete response in bladder cancer. Dozens of clinical-stage ADC programs are advancing across the industry. Every major pharmaceutical company now has an ADC pipeline.
Daiichi Sankyo’s $14.6 billion oncology revenue target by 2030 depends on maintaining leadership in a space it pioneered but no longer dominates alone. The new R&D head must execute against this backdrop while managing the $606 million manufacturing charge the company disclosed in May—a reminder that ADC manufacturing at commercial scale is technically demanding and financially intensive.
The strategic path forward requires innovation on multiple fronts: new targets beyond the HER2 and Trop-2 pathways that current ADCs exploit, improved linker-payload chemistry that delivers more potent anti-tumor effects with fewer side effects, and continued label expansions (Enhertu in early breast cancer, Datroway in first-line TNBC) that move existing products into larger patient populations. The company that started the ADC gold rush must now run faster than the dozens of competitors it inspired.
Curium Wins Novartis Lu-177 Patent Dispute
What Happened: Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications concerning Curium’s Lutetium Lu 177 dotatate product.
Why This Matters for the Radiopharmaceutical Landscape
The ruling clears a legal overhang for Curium’s radiopharmaceutical portfolio and strengthens its competitive position as it pursues the potential $7 billion take-private of Lantheus Holdings (first reported May 23). A successful patent challenge from Novartis could have restricted Curium’s ability to manufacture and sell its Lu-177 product, undermining both its current business and its strategic rationale for the Lantheus acquisition.
Novartis’s Pluvicto (lutetium Lu 177 vipivotide) grew 70% in Q1 2026 and is the leading therapeutic radioligand for prostate cancer. The radioligand therapy market is one of the fastest-growing segments in oncology, with multiple programs in development across prostate cancer, breast cancer, neuroendocrine tumors, and other solid tumor types. Curium’s ability to manufacture Lu-177 products without patent encumbrance from Novartis positions it to compete at the manufacturing and supply level—a critical capability for a company that operates one of the world’s largest radiopharmaceutical production and distribution networks.
If Curium completes the Lantheus take-private, the combined company would be the largest independent radiopharmaceutical company in the world, with capabilities spanning diagnostic imaging (Lantheus PyL for prostate, DEFINITY for cardiac), therapeutic radiopharmaceuticals (Lu-177 production), and a global manufacturing and distribution infrastructure. The patent victory removes a significant legal obstacle to that strategy.
Four Biotechs Have Raised $400M+ in 2026 IPOs
What Happened: BioPharma Dive reported that four biotechs have raised at least $400 million in IPO proceeds in 2026—the most in a single year since 2021. This year’s IPO class has accounted for five of the six largest new biotech stock offerings since the start of 2022.
The Shift in IPO Quality
The key names tell the story: Kailera ($625 million, GLP-1 obesity with Lilly/Hengrui partnership), Parabilis ($475 million, Antibody-Helicon Conjugates with Regeneron partnership), Kardigan ($400 million-plus, cardiovascular pipeline), and one additional company. Total 2026 IPO proceeds now exceed $3.6 billion across 13 companies.
The concentration of large IPOs signals a structural shift in how biotech companies access public markets. These are not early-stage companies testing investor appetite with $100 million raises. They are well-capitalized businesses with validated platforms, existing pharma partnerships, and clinical data that de-risk the investment. The median raise of approximately $300 million across all 2026 IPOs is roughly three times the historical average.
For the broader ecosystem, the quality of the 2026 IPO class reinforces the “back to full health” assessment that PwC delivered earlier this week. When the M&A market is producing $115 billion-plus in deals and the IPO market is producing $3.6 billion-plus in proceeds with four companies raising $400 million or more, both capital market pathways are functioning at levels that support continued biotech innovation and investment. BIO International, opening Monday, provides the next venue where the capital market health translates into actual partnering deals and strategic transactions.
Merck Capvaxive Expanded to Children 2-17
What Happened: Merck won FDA approval to expand Capvaxive (pneumococcal 21-valent conjugate vaccine) to children and adolescents aged 2 to 17 at increased risk of pneumococcal disease.
Why This Matters: The expansion broadens Capvaxive’s addressable population from adults to pediatric high-risk patients. Pneumococcal disease—which includes pneumonia, meningitis, and bloodstream infections—is most dangerous in young children and older adults. Merck’s 21-valent vaccine covers more pneumococcal serotypes than many existing options, positioning it against Pfizer’s dominant Prevnar franchise.
The pediatric expansion gives Merck a competitive entry point in the age group where vaccination programs are most established and physician relationships with vaccine manufacturers are most deeply embedded. Childhood vaccination schedules are set by the CDC’s Advisory Committee on Immunization Practices (ACIP), and inclusion on the childhood schedule is the single most important driver of vaccine market share. While Capvaxive’s initial pediatric approval covers only high-risk children (not the universal childhood schedule), establishing the product in pediatric practice creates familiarity with the vaccine among pediatricians and sets the stage for a potential broader recommendation. Building market share in pediatric vaccination creates a foundation that extends through adult boosters and geriatric care over a patient’s lifetime.
Strategic Themes
1. An mRNA Flu Vaccine Would Be the Most Important Platform Validation Since COVID
COVID proved mRNA could work in an emergency. An approved seasonal flu vaccine would prove mRNA can work as a routine commercial product manufactured at scale, year after year, with consistent efficacy across changing viral strains. The platform validation extends beyond flu: if mRNA produces a better flu vaccine, the same manufacturing infrastructure supports combination respiratory vaccines, pandemic preparedness stockpiles, and rapid-response vaccines for emerging threats (including the Bundibugyo Ebola PHEIC that Moderna is already addressing through a separate partnership).
2. Daiichi Sankyo’s Challenge Is the Classic Innovator’s Dilemma Applied to Drug Development
The company that created the modern ADC category must now compete against dozens of programs inspired by its own success. First-mover advantage in ADCs is real (Enhertu’s clinical data set the benchmark) but not permanent. If Daiichi Sankyo’s next-generation programs do not maintain the efficacy and safety leadership that Enhertu established, the $14.6 billion oncology target becomes significantly harder to reach. The new R&D chief inherits both the opportunity (the ADC market is growing rapidly) and the risk (the competition is growing even faster).
3. Curium’s Patent Win Clears the Path for the Largest Radiopharmaceutical Consolidation in History
The $7 billion Lantheus take-private was already the biggest potential deal in the radiopharmaceutical sector. With the Novartis patent dispute resolved in Curium’s favor, the legal overhang that could have complicated the transaction is gone. If the deal closes, the combined Curium/Lantheus entity would have diagnostic, therapeutic, and manufacturing capabilities that no other independent radiopharmaceutical company can match—creating a vertically integrated platform in one of oncology’s fastest-growing segments.
4. Four $400M+ IPOs in One Year Is the Strongest Signal Yet That the Biotech Capital Cycle Is Fully Functioning
M&A at $115 billion-plus. IPOs at $3.6 billion-plus with four companies exceeding $400 million. PwC declaring the ecosystem “back to full health.” The capital cycle—venture investment funding early innovation, IPOs providing public market liquidity, and M&A completing the cycle through acquisitions—is running at full capacity for the first time since 2021. BIO International opens Monday in San Diego. The partnering conversations that happen there will be shaped by the confidence that both exit pathways (IPO and M&A) are wide open.
Frequently Asked Questions
What did the FDA briefing show about Moderna’s flu vaccine?
The briefing documents indicate the mRNA flu shot met key study goals and may be effective in adults 65 and older. Endpoints said the FDA “provided tepid support” but “didn’t appear to raise any major concerns.” If approved, it would be the first mRNA seasonal flu vaccine in the U.S.
What is Daiichi Sankyo’s ADC challenge?
The company that pioneered modern ADCs with Enhertu now faces competition from Gilead ($15B in ADC acquisitions), Merck (sac-TMT Phase 3 wins), Lilly (CrossBridge), and dozens of clinical-stage programs. The new R&D chief must maintain leadership against the field the company created while hitting a $14.6B oncology revenue target by 2030.
What was the Curium/Novartis ruling?
Curium won a patent dispute with Novartis subsidiary Advanced Accelerator Applications over Lu-177 dotatate. The ruling strengthens Curium’s position as it pursues the potential $7B Lantheus take-private and removes a legal obstacle to its radiopharmaceutical strategy.
How many large biotech IPOs have there been?
Four biotechs have raised at least $400M in 2026 (Kailera $625M, Parabilis $475M, Kardigan $400M+, and one other). The most since 2021. Total IPO proceeds exceed $3.6B across 13 companies.
What is Capvaxive?
Merck’s pneumococcal 21-valent conjugate vaccine. Now expanded to children and adolescents aged 2 to 17 at increased risk. Competes with Pfizer’s Prevnar franchise.
When is BIO International?
Opens Monday, June 22 through June 25 in San Diego.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
mRNA Beyond COVID. We analyze the mRNA flu vaccine’s commercial potential against the established egg-based and cell-based market, assess the manufacturing speed advantage and its impact on strain-match effectiveness, and model what approval means for Moderna’s combination respiratory vaccine pipeline.
ADC Gold Rush. We compile the mid-2026 ADC competitive landscape across Daiichi Sankyo, Merck, Gilead, Lilly, and J&J/Astellas, assess which programs are best positioned to challenge Enhertu’s clinical benchmark, and evaluate whether Daiichi Sankyo’s first-mover advantage is sustainable through 2030.
Radiopharm IP. We analyze how the Curium/Novartis Lu-177 ruling affects the Lantheus take-private timeline, what a combined Curium/Lantheus entity would mean for the broader radiopharmaceutical competitive landscape, and how the Lu-177 manufacturing capability positions against Novartis’s Pluvicto dominance.
Plus: IPO market scorecard, Merck Capvaxive pediatric franchise analysis, BIO International preview, Revolution filing watch, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
